Last reviewed · How we verify
Verapamil Pill
Verapamil Pill is a Small molecule drug developed by Biogen. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Biogen is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Verapamil Pill |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hyperglycemia
- Covid-19
- Headache
- Upper Respiratory Infection
- Gastroenteritis
- Vomiting
- Viral Syndrome
- Sore Throat
- 2nd Degree Heart Block
- Cardiac Arrhythmia
- 1st Degree Heart Block
- Premature Ventricular Contractions
Key clinical trials
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Management of Acute Tinnitus With Migraine Medications (PHASE4)
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone (PHASE1)
- Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (PHASE3)
- Treatment of Tinnitus With Migraine Medications (PHASE4)
- Ranolazine and Microvascular Angina by PET in the Emergency Department (PHASE4)
- Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery (PHASE3)
- Drug Discrimination in Methadone-Maintained Humans Study 3 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Verapamil Pill CI brief — competitive landscape report
- Verapamil Pill updates RSS · CI watch RSS
- Biogen portfolio CI
Frequently asked questions about Verapamil Pill
What is Verapamil Pill?
Who makes Verapamil Pill?
What development phase is Verapamil Pill in?
What are the side effects of Verapamil Pill?
Related
- Manufacturer: Biogen — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing